Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Liabilities (2020 - 2024)

Puma Biotechnology's Other Non-Current Liabilities history spans 5 years, with the latest figure at $121000.0 for Q4 2024.

  • For Q4 2024, Other Non-Current Liabilities changed 0.0% year-over-year to $121000.0; the TTM value through Dec 2024 reached $121000.0, changed 0.0%, while the annual FY2024 figure was $121000.0, 0.0% changed from the prior year.
  • Other Non-Current Liabilities reached $121000.0 in Q4 2024 per PBYI's latest filing, roughly flat from $121000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $26.0 million in Q4 2020 to a low of $37000.0 in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.9 million, with a median of $121000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 99.86% in 2021, then soared 19875.68% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $26.0 million in 2020, then tumbled by 99.86% to $37000.0 in 2021, then skyrocketed by 19875.68% to $7.4 million in 2022, then tumbled by 98.36% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024.
  • Per Business Quant, the three most recent readings for PBYI's Other Non-Current Liabilities are $121000.0 (Q4 2024), $121000.0 (Q3 2024), and $121000.0 (Q2 2024).